{"id":656441,"date":"2026-10-25T07:48:13","date_gmt":"2026-10-25T07:48:13","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/656441\/"},"modified":"2026-10-25T07:48:13","modified_gmt":"2026-10-25T07:48:13","slug":"tenecteplase-benefit-before-thrombectomy-varies-by-stroke-cause-study-shows-neurologylive","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/656441\/","title":{"rendered":"Tenecteplase Benefit Before Thrombectomy Varies by Stroke Cause, Study Shows | NeurologyLive"},"content":{"rendered":"\n<p class=\"\">READ MORE: <a href=\"https:\/\/www.neurologylive.com\/endovascular-therapy-benefit-distal-vessel-stroke-tied-severity-not-ivt-status\" target=\"_blank\" rel=\"nofollow noopener\">Endovascular Therapy Benefit in Distal Vessel Stroke Tied to Severity, Not IVT Status<\/a><\/p>\n<p class=\"\">Among patients with LAA, mortality was higher with tenecteplase (HR, 2.08; 95% CI, 1.03-4.22), giving rates of 14.1% and 29.3% between the 2 arms; unlike the functional outcome and hemorrhage figures elsewhere in the abstract, the arm order for this specific pair of rates was not stated explicitly.1<\/p>\n<p class=\"\">The investigators concluded that stroke etiology appeared to modify the effect of pre-thrombectomy tenecteplase in large vessel occlusion treated within 4.5 hours. Patients with CE stroke appeared more likely to derive functional benefit from tenecteplase, while patients with LAA did not, despite higher rates of reperfusion before thrombectomy in the tenecteplase group.<\/p>\n<p>The BRIDGE-TNK trial and its primary results<\/p>\n<p class=\"\">BRIDGE-TNK was an investigator-initiated, multicenter, randomized, open-label trial conducted at 40 thrombectomy-capable centers in China between May 9, 2022, and September 8, 2024. Patients with acute large vessel occlusion stroke who were eligible for intravenous thrombolysis within 4.5 hours of last known well were randomized 1:1 to tenecteplase (0.25 mg\/kg, maximum 25 mg) followed by EVT or to EVT alone, with a primary outcome of functional independence (mRS score 0-2) at 90 days. The study was sponsored in part by CSPC Recomgen Pharmaceutical, which supplied the tenecteplase.2<\/p>\n<p class=\"\">In the trial&#8217;s primary results, published in May 2025, 550 patients were randomized (278 to tenecteplase plus EVT, 272 to EVT alone). Functional independence at 90 days was achieved by 52.9% of patients who received tenecteplase before EVT versus 44.1% of those who received EVT alone (RR, 1.20; 95% CI, 1.01-1.43; P =.04), meeting the trial&#8217;s primary endpoint. Symptomatic intracranial hemorrhage within 48 hours occurred in 8.5% of the tenecteplase group versus 6.7% of the EVT-alone group, and 90-day mortality was 22.3% versus 19.9%; neither difference reached statistical significance.2<\/p>\n<p class=\"\">For more WSC 2026 coverage, <a href=\"https:\/\/www.neurologylive.com\/conferences\/wsc\" target=\"_self\" rel=\"nofollow noopener\">click here.<\/a><\/p>\n<p>REFERENCES<br \/>1. Ruan Z, et al. Effect of stroke etiology on outcomes of tenecteplase plus thrombectomy versus thrombectomy alone: a secondary analysis of the BRIDGE-TNK trial. Presented at: World Stroke Congress 2026 (WSC 2026); October 21-23, 2026; Seoul, Republic of Korea.<br \/>2. Qiu Z, Li F, Sang H, et al. Intravenous tenecteplase before thrombectomy in stroke. N Engl J Med. 2025;393(2):139-150. doi:10.1056\/NEJMoa2503867 <\/p>\n","protected":false},"excerpt":{"rendered":"READ MORE: Endovascular Therapy Benefit in Distal Vessel Stroke Tied to Severity, Not IVT Status Among patients with&hellip;\n","protected":false},"author":2,"featured_media":656442,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[163,85,46],"class_list":["post-656441","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/656441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=656441"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/656441\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/656442"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=656441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=656441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=656441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}